267 related articles for article (PubMed ID: 29288428)
1. Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG.
Scappaticci GB; Marini BL; Nachar VR; Uebel JR; Vulaj V; Crouch A; Bixby DL; Talpaz M; Perissinotti AJ
Ann Hematol; 2018 Apr; 97(4):573-584. PubMed ID: 29288428
[TBL] [Abstract][Full Text] [Related]
2. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.
Nazha A; Kantarjian H; Ravandi F; Huang X; Choi S; Garcia-Manero G; Jabbour E; Borthakur G; Kadia T; Konopleva M; Cortes J; Ferrajoli A; Kornblau S; Daver N; Pemmaraju N; Andreeff M; Estrov Z; Du M; Brandt M; Faderl S
Am J Hematol; 2013 Nov; 88(11):961-6. PubMed ID: 23877926
[TBL] [Abstract][Full Text] [Related]
3. The fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG) chemotherapy regimen is an alternative to anthracycline-based therapy for the treatment of acute myeloid leukemia for patients with pre-existing cardiac disease.
Saini L; Brandwein J; Turner R; Larratt L; Hamilton M; Peters A; Wu C; Zhu N; Patterson JM; Bolster L; Mant M; Ritchie B; Liew E; Ghosh S; Sandhu I
Eur J Haematol; 2016 Nov; 97(5):471-478. PubMed ID: 27028202
[TBL] [Abstract][Full Text] [Related]
4. G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.
Becker PS; Medeiros BC; Stein AS; Othus M; Appelbaum FR; Forman SJ; Scott BL; Hendrie PC; Gardner KM; Pagel JM; Walter RB; Parks C; Wood BL; Abkowitz JL; Estey EH
Am J Hematol; 2015 Apr; 90(4):295-300. PubMed ID: 25545153
[TBL] [Abstract][Full Text] [Related]
5. Clofarabine in the treatment of elderly patients with acute myeloid leukemia.
Aleem A; Anjum F; Algahtani F; Iqbal Z; Alsaleh K; Almomen A
Asian Pac J Cancer Prev; 2013; 14(2):1089-92. PubMed ID: 23621192
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.
Jabbour E; Short NJ; Ravandi F; Huang X; Xiao L; Garcia-Manero G; Plunkett W; Gandhi V; Sasaki K; Pemmaraju N; Daver NG; Borthakur G; Jain N; Konopleva M; Estrov Z; Kadia TM; Wierda WG; DiNardo CD; Brandt M; O'Brien SM; Cortes JE; Kantarjian H
Cancer; 2017 Nov; 123(22):4430-4439. PubMed ID: 28708931
[TBL] [Abstract][Full Text] [Related]
7. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.
Estey E; Thall P; Andreeff M; Beran M; Kantarjian H; O'Brien S; Escudier S; Robertson LE; Koller C; Kornblau S
J Clin Oncol; 1994 Apr; 12(4):671-8. PubMed ID: 7512125
[TBL] [Abstract][Full Text] [Related]
8. Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience.
Tavil B; Aytac S; Balci YI; Unal S; Kuskonmaz B; Yetgin S; Gurgey A; Tuncer M; Gumruk F; Uckan D; Cetin M
Pediatr Hematol Oncol; 2010 Oct; 27(7):517-28. PubMed ID: 20677923
[TBL] [Abstract][Full Text] [Related]
9. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.
Faderl S; Ravandi F; Huang X; Wang X; Jabbour E; Garcia-Manero G; Kadia T; Ferrajoli A; Konopleva M; Borthakur G; Burger J; Feliu J; Kantarjian HM
Cancer; 2012 Sep; 118(18):4471-7. PubMed ID: 22282348
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
Xu J; Lv TT; Zhou XF; Huang Y; Liu DD; Yuan GL
Medicine (Baltimore); 2018 Sep; 97(39):e12102. PubMed ID: 30278488
[TBL] [Abstract][Full Text] [Related]
11. Cost of de novo acute myeloid leukemia induction therapy in adults: analysis of EORTC-GIMEMA AML10 and FLANG regimens.
Clavio M; Quintino S; Masoudi B; Carrara S; Cerri R; Pierri I; Canepa L; Miglino M; Muner P; Damasio E; Gobbi M
J Exp Clin Cancer Res; 2001 Jun; 20(2):165-73. PubMed ID: 11484970
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of CLARA in recurrent/refractory acute myeloid leukaemia patients unresponsive to FLAG chemotherapy.
Kaya AH; Tekgündüz E; Ilkkiliç K; Dal MS; Merdin A; Karakus A; Hacioglu SK; Bekdemir F; Çakar MK; Dogu MH; Ayyildiz MO; Korkmaz S; Altuntaş F;
J Chemother; 2018 Feb; 30(1):44-48. PubMed ID: 29098953
[TBL] [Abstract][Full Text] [Related]
13. Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia.
Hänel M; Friedrichsen K; Hänel A; Herbst R; Morgner A; Neser S; Nicklisch M; Teich M; Ehninger G; Fiedler F
Onkologie; 2001 Aug; 24(4):356-60. PubMed ID: 11574763
[TBL] [Abstract][Full Text] [Related]
14. Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients.
Takahashi K; Kantarjian H; Garcia-Manero G; Borthakur G; Kadia T; DiNardo C; Jabbour E; Pierce S; Estrov Z; Konopleva M; Andreeff M; Ravandi F; Cortes J
Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):163-8.e1-2. PubMed ID: 26752456
[TBL] [Abstract][Full Text] [Related]
15. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML.
Löwenberg B; Pabst T; Maertens J; van Norden Y; Biemond BJ; Schouten HC; Spertini O; Vellenga E; Graux C; Havelange V; de Greef GE; de Weerdt O; Legdeur MJ; Kuball J; Kooy MV; Gjertsen BT; Jongen-Lavrencic M; van de Loosdrecht AA; van Lammeren-Venema D; Hodossy B; Breems DA; Chalandon Y; Passweg J; Valk PJ; Manz MG; Ossenkoppele GJ;
Blood; 2017 Mar; 129(12):1636-1645. PubMed ID: 28049642
[TBL] [Abstract][Full Text] [Related]
17. Retrospective Analysis of Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia Treated with FLAG at a Comprehensive Cancer Center.
Tenold ME; Moskoff BN; Krishnan R; Rosenberg AS; Hoeg RT; Abedi M; Tuscano JM; Jonas BA
Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):e611-e618. PubMed ID: 33811007
[TBL] [Abstract][Full Text] [Related]
18. FLAG salvage therapy combined with idarubicin in relapsed/refractory acute myeloid leukemia.
Westhus J; Noppeney R; Dührsen U; Hanoun M
Leuk Lymphoma; 2019 Apr; 60(4):1014-1022. PubMed ID: 30277107
[TBL] [Abstract][Full Text] [Related]
19. A prospective, multicenter phase II study of continuous infusion of FLAG for patients older than 60 yr with resistant acute myeloid leukemia: a comparison with intensive younger patients' trial.
Kim H; Lee JH; Joo YD; Bae SH; Lee JH; Kim DY; Lee WS; Ryoo HM; Jo JC; Choi Y; Lee KH;
Eur J Haematol; 2016 Feb; 96(2):188-97. PubMed ID: 25891993
[TBL] [Abstract][Full Text] [Related]
20. [Effects of FLAG protocol in treatment of the first time induced non-remission acute myeloid leukemia].
Wang SH; Yu L; Wang QS; Li HH; Zhao Y; Li F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec; 15(6):1297-9. PubMed ID: 18088488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]